|drug1341||mesenchymal stem cells Wiki||1.00|
|drug1365||oxygen therapy Wiki||0.71|
There is one clinical trial.
The outbreak of coronavirus disease 2019 (COVID-19) at the end of 2019 has seen numerous patients experiencing severe acute lung injury (ALI), which developed into severe respiratory distress syndrome (ARDS). The mortality was as high as 20% -40%. Due to the lack of effective antiviral treatments, supporting treatment is the predominant therapy for COVID-19 pneumonia. Its cure is essentially dependent on the patient's immunity. While the immune system eliminates the virus, numerous inflammatory cytokines are produced and a cytokine storm occurs in severe cases. Mesenchymal stem cells (MSCs) play an important role in injury repair and immune regulation, showing advantageous prospects in the treatment of COVID-19 pneumonia. MSCs prevent cytokine storms by retarding the TNF-α pathway, alleviate sepsis by modulating macrophages, neutrophils, NK cells, DC cells, T lymphocytes and B lymphocytes. After infused, MSCs aggregate in the lungs, improve the lung microenvironment, protect alveolar epithelia, and improve pulmonary fibrosis and pulmonary function.
Description: Improvement of pulmonary functionMeasure: Changes of oxygenation index (PaO2/FiO2) ,blood gas test Time: 12 months
Description: Cytokines levelMeasure: Detection of TNF-α levels, IL-10 levels Time: 1,3,6,12months
Description: Immunological statusMeasure: Detection of immune cells that secret cytokines, including CXCR3+, CD4+, CD8+, NK+ cells, and regulatory T cells (CD4 + CD25 + FOXP3 + Treg cells). Time: 1,3,6,12months
Description: Improvement of pulmonary functionMeasure: Changes of oxygenation index (PaO2/FiO2) ,blood gas test Time: 1,3,6months
Description: Infection biomarkersMeasure: Changes of c-reactive protein and calcitonin Time: 1,3,6,12months